-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insider Buying: Antibe Therapeutics Inc. (TSE:ATE) Senior Officer Acquires C$12,400.00 in Stock
Insider Buying: Antibe Therapeutics Inc. (TSE:ATE) Senior Officer Acquires C$12,400.00 in Stock
Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis bought 20,000 shares of the stock in a transaction on Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the purchase, the insider now directly owns 80,000 shares in the company, valued at approximately C$49,600.
ATE stock opened at C$0.60 on Thursday. The stock has a market capitalization of C$30.83 million and a P/E ratio of -1.12. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. Antibe Therapeutics Inc. has a one year low of C$0.59 and a one year high of C$3.65. The company has a 50 day moving average price of C$0.66 and a two-hundred day moving average price of C$0.70.
Get Antibe Therapeutics alerts:About Antibe Therapeutics (Get Rating)
Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.Recommended Stories
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis bought 20,000 shares of the stock in a transaction on Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the purchase, the insider now directly owns 80,000 shares in the company, valued at approximately C$49,600.
安提貝治療公司(多倫多證券交易所代碼:ATE-GET評級)高級官員斯科特·威爾遜·柯蒂斯在7月8日星期五的一筆交易中購買了2萬股該股。該股是以每股0.62加元的平均成本購買的,總價值為12,400.00加元。收購完成後,這位內部人士現在直接擁有該公司8萬股,價值約49,600加元。
ATE stock opened at C$0.60 on Thursday. The stock has a market capitalization of C$30.83 million and a P/E ratio of -1.12. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. Antibe Therapeutics Inc. has a one year low of C$0.59 and a one year high of C$3.65. The company has a 50 day moving average price of C$0.66 and a two-hundred day moving average price of C$0.70.
ATE股票週四開盤報0.60加元。該股市值為3,083萬加元,市盈率為-1.12。該公司的負債權益比率為0.29,速動比率為11.92,流動比率為13.07。安提貝治療公司的股價一年來最低為0.59加元,一年最高為3.65加元。該公司的50日移動均線價格為0.66加元,200日移動均線價格為0.70加元。
About Antibe Therapeutics (Get Rating)
關於安提貝治療公司(獲取評級)
Recommended Stories
推薦故事
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
- 下半年將再考慮3只股票
- 聯合天然食品庫存準備好被點心
- 彈性股票是一種活躍的搜索業務
- 3M(紐約證券交易所代碼:MMM)評級下調後,現在是買入3M的好時機嗎?
- 蘋果全球智能手機市場份額增長20%,你應該考慮股票嗎?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《安提貝治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對安替比治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧